|
 |
|
|
|||
|
 |
|
Aug. 14, 2023 Source: Elanco news release Second Quarter 2023 Financial Results *Revenue of $1,057 million, impacted by an estimated $90-$110 million of revenue related to customer purchasing shifted from the second quarter into the first as a result of ERP system commercial ordering blackout period for legacy Bayer Animal Health products in April *Reported Net Loss of $(97) million, Adjusted Net Income of $90 million *Adjusted EBITDA of $222 million or 21.0% of Revenue *Reported EPS of $(0.20), Adjusted EPS of $0.18 *Net leverage ratio of 5.9x Adjusted EBITDA Raising full year 2023 guidance ranges to reflect current assumptions: *Revenue of $4,350 to $4,410 million *Reported Net Loss of $127 to $170 million, Reported diluted EPS of $(0.34) to $(0.26) *Adjusted EPS of $0.80 to $0.89, Adjusted EBITDA of $950 to $1,010 million *Net leverage ratio expected at 5.5x to 5.8x Adjusted EBITDA at year-end 2023 *Announced the Environmental Protection Agency (EPA) completed its review of Seresto, confirming continued registration To read the entire report click here. Tweet |
|
|
|
|
|
|
|
|
|||||||||||||
